Wave Life Sciences Q2 net loss narrows to $21.1M; revenue jumps to $22.1M on GSK collaboration

Wave Life Sciences Ltd.

2023-Q2 EPS reported -$0.47 revenue$35,035,000

Net loss of $21.1M vs $41.3M YoY; revenue of $22.1M from GSK/Takeda collaborations vs $0.4M in Q2 2022.
Cash and equivalents $173.0M at June 30, 2023, up from $88.5M at Dec 2022; runway into 2025.
Imminent CTA submission for WVE-006 (AATD RNA editing candidate); first-in-human study expected 2H 2023.
DMD candidate WVE-N531 on track for potentially registrational Phase 2 dosing in 2H 2023; dystrophin data in 2024.
Discontinued WVE-004 for C9-ALS/FTD, but biomarker data validated PN chemistry; HD candidate WVE-003 multi-dose dosing underway.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Wave Life Sciences Ltd. reported the quarter ended June 30, 2023 results: revenue $22.1 million, net income a net loss of $21.1 million.

Period: the quarter ended June 30, 2023
Revenue: $22.1 million
Net income: a net loss of $21.1 million
Result: reported results

Exact text from the filing

under the company’s collaboration with GSK, which became effective January 27, 2023. Revenue recognized under the GSK and Takeda collaborations in the second quarter of 2023 was $22.1 million. During the second quart

View on SEC.gov

Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-202288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.